LGM
ABCL icon

Logos Global Management’s AbCellera Biologics ABCL Stock Holding History

Logos Global Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300,000
Closed -$12.1M – 54
2020
Q4 		$12.1M Buy
+300,000
New +$13.7M 1.03% 23

Other funds holding ABCL

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Logos Global Management's ABCL Position: Q1 2021 in Review

Logos Global Management sold out of AbCellera Biologics (ABCL) in Q1 2021, closing a stake of 300,000 shares — an estimated $12.1M sold.

Logos Global Management first reported a position in ABCL in Q4 2020 and held it in 1 quarter. The position peaked at $12.1M in Q4 2020. 86 funds tracked by Wall St. Rank hold ABCL as of Q1 2021.

  • Logos Global Management reported no remaining AbCellera Biologics position as of Q1 2021 after selling out during the quarter.
  • Logos Global Management sold 300,000 AbCellera Biologics shares in Q1 2021, an estimated $12.1M.
  • Logos Global Management first reported a position in AbCellera Biologics in Q4 2020 and held it in 1 quarter.
  • Logos Global Management's AbCellera Biologics position peaked at $12.1M in Q4 2020.
  • 86 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2021.

Based on Logos Global Management's 13F filing for Q1 2021, filed 17 May 2021.